オプションチェーンは、Viatrisの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Viatrisの市場センチメントを評価します。.

Viatris (NASDAQ:VTRS) 株価情報, オプションチェーン

Viatris

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris Inc

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) to report quarterly earnings at $1.94 per share on revenue of $27.89 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. PepsiCo shares fell 0.2% to $150.01 in after-hours trading.</li>
<li>NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) posted upbeat earnings and sales results for its fourth quarter on Monday. The company also said it sees first-quarter adjusted earnings of $2.39 to $2.79 per share on revenue of $2.725 billion to $2.925 billion. NXP Semiconductors shares gained 2.4% to $209.71 in the after-hours trading session.</li>
<li>Analysts are expecting Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) to post quarterly earnings at 47 cents per share on revenue of $17.40 billion. The company will release earnings before the markets open. Pfizer shares gained 0.5% to $26.32 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>UBS Group AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) reported stronger-than-expected earnings for its fourth quarter and disclosed a share buyback program of up to $3 billion. Switzerland&#8217;s largest bank reported quarterly net income of $770 million for the fourth quarter, beating estimates. UBS shares fell 0.1% to $34.90 in the after-hours trading session.</li>
<li>Analysts expect Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) to post quarterly earnings at $3.08 per share on revenue of $2.32 billion after the closing bell. Electronic Arts shares gained 0.4% to $123.39 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock">Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

NXPI

PepsiCo, Pfizer And 3 Stocks To Watch Heading Into Tuesday

Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) witnessed electric vehicle sales soar 21.2% in the U.S. in January despite a drop in sales of both its E-transit van and F-150 Lightning truck.
EV Sales Buoyed By Mustang Mach-E: Ford <a href="https://www.benzinga.com/25/01/42801670/mustang-mach-e-spurs-fords-ev-sales-in-q4-after-it-delays-new-vehicle-launch">sold 5,666 electric vehicles</a> in January as compared to the 4,674 sold in the corresponding period of last year, the company said on Monday.
The rise in sales was purely due to the surge in sales of the company&#8217;s Mustang Mach-E electric SUV. Ford sold 3,529 units of the SUV in January as compared to just 1,295 in January 2024. 
The F-150 Lightning, meanwhile, witnessed a 15.5% dip in sales to 1,907 units while the E-Transit witnessed an 80% dip to 230 units.
In 2024, Mach-E sales <a href="https://www.benzinga.com/25/01/42938610/ford-sold-more-electric-mustangs-than-gas-mustangs-in-2024">exceeded 50,000 units</a>, trumping the sales number of its gas-powered counterpart Mustang for the first time. Customer orders for the 2025 Mustang Mach-E opened in January end. 
Internal Combustion Vehicles Weigh Down Overall Sales: Ford&#8217;s overall deliveries across propulsion types fell 6.3% to 142,944 units, following a 9.4% drop in internal combustion engine vehicle sales. The <a href="https://www.benzinga.com/news/24/10/41183132/us-regulator-opens-probe-into-more-than-368k-ford-edge-vehicles-over-concerns-of-loss-of-braking">Ford Edge SUV </a>witnessed a massive 91% drop in sales to just 633 units after its production ended in North America in April. 
Hybrid vehicle sales jumped 19.2% year-over-year to 13,295 units. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43427393/tesla-rival-byd-marks-475-growth-in-january-passenger-vehicle-sales-driven-by-popularity-of-plug-in-hybrid-evs" target="_blank" rel="noreferrer noopener">Tesla Rival BYD Marks 47.5% Growth In January Passenger Vehicle Sales Driven By Popularity Of Plug-In Hybrid EVs</a></li>
</ul>
Photo courtesy: Ford

Tech

Mustang Mach-E Accelerates Ford's EV Sales In January Even As F-150 Lightning Slows Down

<ul>
<li>NYFIX Matching is the first post-trade matching tool with messaging functionality, enabling compliance, greater transparency and streamlined resolution of post-trade discrepancies</li>
</ul>

Broadridge Integrates Symphony Messaging Into NYFIX Matching, Enhancing Post-Trade Efficiency

Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has quietly removed a workaround that allowed users to install Windows 11 on unsupported PCs.
What Happened: The workaround, initially provided when Windows 11 version 21H2 was released, enabled users to bypass system requirements, including TPM 2.0 and specific CPU models.
However, the support document containing this information has been edited, removing the workaround after the release of Windows 11 24H2, as first <a href="https://www.neowin.net/news/microsoft-quietly-removes-official-windows-11-cputpm-bypass-for-unsupported-pcs/">spotted</a> by Neowin.
Microsoft&#8217;s official stance discourages installing Windows 11 on devices that do not meet the minimum system requirements. Users are advised to verify their device compatibility using the PC Health Check app.
See Also: <a href="https://www.benzinga.com/tech/25/02/43453553/palantirs-shyam-sankar-us-is-at-war-with-china-in-ai-and-the-time-to-act-was-yesterday">Palantir&#8217;s Shyam Sankar: US Is At War With China In AI—And The Time To Act Was &#8216;Yesterday&#8217;</a>
The company has previously warned about the potential loss of hardware and software support for unsupported upgrades.
While some users have upgraded to Windows 11, about 400 million users remain on Windows 10 due to hardware limitations, according to a Forbes <a href="https://www.forbes.com/sites/zakdoffman/2025/02/03/microsoft-warns-400-million-users-do-not-update-windows/">report</a>. Microsoft suggests purchasing new PCs, ideally with AI features, for those unable to meet the upgrade requirements.
Microsoft did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga's</a> request for comments.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Last month, Microsoft posted quarterly GAAP earnings of $3.23 per share, surpassing the consensus estimate of $3.11. The <a href="https://www.benzinga.com/news/earnings/25/01/43320124/microsoft-shares-slide-after-q2-results-cloud-revenue-misses-expectations-details">company&#8217;s revenue</a> for the quarter reached $69.6 billion, exceeding analysts&#8217; expectations of $68.78 billion.
As of January 2025, Windows 10 remains the leading desktop operating system globally, commanding a 60.37% market share, according to Statcounter Global Stats report tracking the distribution of Microsoft&#8217;s operating system versions across desktop computers.
Windows 11 continues to gain traction, capturing 36.6% of the market. Despite being officially unsupported, Windows 7 still accounts for 2.24% of users, while Windows 8.1 and Windows XP maintain marginal shares of 0.3% and 0.27%, respectively. Windows 8 lags with just 0.16% of the market.
Image via Shutterstock
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43221770/apples-ipad-turns-15-today-heres-a-throwback-to-when-steve-jobs-explained-called-it-the-third-category-after-phones-and-notebooks" target="_blank" rel="noreferrer noopener">Apple&#8217;s iPad Turns 15 Today: Here&#8217;s A Throwback To When Steve Jobs Explained Called It The ‘Third Category&#8217; After Phones And Notebooks</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

MSFT

Windows 11 Disaster? Microsoft Quietly Removes Workaround For Unsupported PCs, Potentially Leaving Millions Unable To Upgrade

Collaboration delivers greater agility, operational efficiency and speed to market, driving customer satisfaction and loyalty

CSGS

CSG's CPQ Platform Empowers Gamma To Deliver Faster, More Personalized Telecom Solutions

Outlook for Q2 FY 2025: Based on an assumed exchange rate of US$1.05 to the euro, revenue of around €3.6 billion expected. On this basis, Segment Result Margin forecast to be in the mid-teens percentage range – Outlook for FY 2025: Based on an assumed exchange rate of US$1.05 to the euro (previously US$1.10), revenue is now expected to be flat to slightly up (previously: to decline slightly) compared with the prior year. The adjusted gross margin should be around 40 percent and the Segment Result Margin in the midto-high-teens percentage range. Investments of approximately €2.5 billion planned. Free Cash Flow adjusted for investments in frontend buildings should be around €1.7 billion and reported Free Cash Flow around €900 million

Guidance

IFNNY

Infineon Raises FY 2025 Revenue Outlook To Flat Or Slight Growth (Prior Decline Slightly), Citing Favorable Exchange Rates And Plans €2.5B In Investments

Infineon Technologies (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IFNNY#OTC">IFNNY</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.27 by 30.37 percent. This is a 38.25 percent decrease over earnings of $0.57 per share from the same period last year. The company reported quarterly sales of $3.65 billion which beat the analyst consensus estimate of $3.21 billion by 13.84 percent. This is a 8.30 percent decrease over sales of $3.98 billion the same period last year.

Infineon Technologies Q1 EPS $0.35 Beats $0.27 Estimate, Sales $3.65B Beat $3.21B Estimate

Looking ahead, we are confident in our growth outlook and competitive positioning.&nbsp;
As such, for 2025 we anticipate total revenue growth between 6% and 8%, operating margin expansion of 70-100 basis points and EPS up 7% to 10%.

DASTY

Dassault Systèmes For 2025 Projects 6%-8% Revenue Growth, 70-100 Bps Operating Margin Expansion, And 7%-10% EPS Increase

Dassault Systemes (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DASTY#OTC">DASTY</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.36 by 19.44 percent. This is a 10.26 percent increase over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $1.88 billion which beat the analyst consensus estimate of $1.76 billion by 6.82 percent. This is a 6.27 percent increase over sales of $1.77 billion the same period last year.

Dassault Systemes Q4 Adj. EPS $0.43 Beats $0.36 Estimate, Sales $1.88B Beat $1.76B Estimate

AudioCodes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUDC#NASDAQ">AUDC</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.23 by 60.87 percent. This is a 32.14 percent increase over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $61.554 million which beat the analyst consensus estimate of $61.510 million by 0.07 percent. This is a 3.15 percent decrease over sales of $63.559 million the same period last year.

Earnings Beats

AUDC

AudioCodes Q4 2024 Adj. EPS $0.37 Beats $0.23 Estimate, Sales $61.554M Beat $61.510M Estimate

2. FY25 forecast: Revenue ¥5,400.0 bn (+¥10.0 bn compared to the previous announcement), Operating Profit ¥400.0 bn (unchanged from the previous announcement)
- Due mainly to foreign exchange rates reconsidered in line with the weaker yen, revenue is expected to exceed the previous announcement.
- Mitsubishi Electric Group will steadily implement ongoing initiatives to improve profitability and efficiency in each business.

MIELF

MIELY

Mitsubishi Electric Revises FY25 Revenue Forecast To ¥5.4T, Maintains Operating Profit at ¥400B

Mitsubishi Electric Q3 Sales ¥1.356T ($8.81B) Up From ¥1.243T YoY; Net Profit Attributable Stockholders ¥129.4B Up From ¥65.8B YoY

Investor sentiment remained positive in the fourth quarter of 2024, driving strong institutional and private client activity supported by a constructive market backdrop that reflected an increase in investors' risk appetite following the results of the US presidential election.&nbsp;
Constructive market conditions have continued into the first quarter of 2025 sustained by the greater optimism regarding growth prospects in the US. However, investor behavior may be affected by the clouded macroeconomic outlook outside the US, increased uncertainties around global trade, inflation and central bank policies, as well as geopolitics, including the upcoming elections in Germany. We see the markets as remaining particularly sensitive to new developments, positive or negative, leading to potential spikes in volatility across all asset classes.&nbsp;
In the first quarter, we expect a low-to-mid single digit percentage sequential decline in net interest income (NII) in Global Wealth Management and around a 10% sequential decline in Personal &amp; Corporate Banking's NII, measured in Swiss francs. Higher asset levels are expected to support recurring fee income across our asset-gathering businesses. As we progress our integration plans, integration-related expenses are expected to be around USD 1.1bn and accretion of PPA effects to contribute around USD 0.5bn to the Group's total revenues.&nbsp;
We remain focused on supporting clients with advice and solutions and continue to execute on our priorities, investing in people, products, and capabilities to drive sustainable long-term value for our stakeholders while maintaining a balance sheet for all seasons.

UBS Forecasts Q1 Decline In Net Interest Income Amid Integration Costs And Strategic Investments

In response to the United States&#8217; unilateral decision to impose a 10% tariff on all Chinese goods, China has announced its intention to retaliate by imposing tariffs on certain US imports.
What Happened: The State Council Customs Tariff Commission announced on Tuesday that it will be imposing tariffs on certain US imports, effective from Feb. 10. The decision comes in response to the U.S. government&#8217;s decision to levy a 10% tariff on all Chinese goods.
According to the announcement, the tariffs will be as follows:
1. A 15% tariff on coal and liquefied natural gas (LNG).
2. A 10% tariff on crude oil, agricultural machinery, high-displacement vehicles, and pickup trucks.
3. Additional tariffs will be imposed on the listed U.S. imports, on top of the existing rates. The current tax exemption and reduction policies will remain unchanged, and the additional tariffs will not be subject to reduction.
SEE ALSO:&nbsp;<a href="https://in.benzinga.com/25/02/43452717/nvidia-tsmc-drop-as-trump-hits-mexico-canada-and-china-with-tariffsbut-top-analyst-sees-only-limited-supply-chain-impact">Nvidia, TSMC Stocks Fell As Trump Hit Mexico, Canada, And China With Tariffs—But Top Analyst Sees Only &#8216;Limited&#8217; Supply Chain Impact On Chips</a>
The announcement was made according to the laws of the People&#8217;s Republic of China, including the Customs Law, the Foreign Trade Law, and international legal principles. The decision was approved by the State Council.
In a separate statement, officials from the Chinese Commerce Ministry and customs announced the implementation of export controls on items related to tungsten, tellurium, ruthenium, and molybdenum.
Why It Matters: The decision by China to impose tariffs on select US imports comes in response to the US government&#8217;s decision to levy a 10% tariff on all Chinese goods. This move is part of the ongoing trade tensions between the two economic powerhouses, which have been escalating in recent years.
President Donald Trump&#8216;s tariffs on Canada, Mexico, and China are predicted to <a href="https://www.benzinga.com/news/global/25/02/43442219/why-beer-tequila-avocados-cars-iphone-prices-could-rise-trumps-tariffs-on-canada-mexico-china-to-hurt-several-sectors">impact several sectors</a> and potentially lead to retailers and companies raising prices on consumers to offset the higher prices.
Renowned economist and Obama-era Treasury Secretary, Lawrence Summers, criticized President Trump's recent tariff impositions, <a href="https://www.benzinga.com/25/02/43425160/trump-tariffs-a-strategic-gift-to-xi-jinpings-china-says-obama-era-treasury-secretary-jobs-in-industrial-heartland-will-be-lost">describing them as a "bully strategy"</a> that could have far-reaching negative impacts.
Among crude oil and LNG exporters, companies like Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), and ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>), which have significant exports to China, could see higher costs due to the new tariffs. Similarly, U.S. automakers such as General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Ford (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), which sell vehicles in China, may encounter new challenges.
<ul>
<li>READ NEXT: <a href="https://www.benzinga.com/tech/25/02/43453553/palantirs-shyam-sankar-us-is-at-war-with-china-in-ai-and-the-time-to-act-was-yesterday">Palantir&#8217;s Shyam Sankar: US Is At War With China In AI—And The Time To Act Was &#8216;Yesterday&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Macro Economic Events

Economics

China Strikes Back: New Tariffs Up To 15% On Certain US Imports In Retaliation For Trump's 10% Levy On Chinese Goods

UBS Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.22 by 4.55 percent. This is a 355.56 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $11.635 billion which beat the analyst consensus estimate of $11.171 billion by 4.15 percent. This is a 7.19 percent increase over sales of $10.855 billion the same period last year.

UBS Gr Q4 2024 GAAP EPS $0.23 Beats $0.22 Estimate, Sales $11.635B Beat $11.171B Estimate

<ul>
<li>Dassault Systèmes' 3DEXPERIENCE platform on the cloud becomes a foundational technology solution at Volkswagen Group to advance vehicle development</li>
<li>Virtual twin experiences reduce engineering and manufacturing cycles of complex automotive systems, streamline workflows, optimize resources and accelerate time-to-market</li>
</ul>

VLVLY

Volkswagen Partners With Dassault Systèmes To Leverage Cloud-Based 3DEXPERIENCE Platform For Smarter, Faster Car Development

Tyson Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) reported better-than-expected first-quarter results, driven by robust performance in the chicken sales segment. This marks the company&#8217;s third consecutive quarter of annual growth across key metrics.
What Happened: The company <a href="https://www.benzinga.com/news/earnings/25/02/43432806/tyson-foods-posts-q1-earnings-protein-conscious-customers-drive-demand-ceo-calls-it-best-quarter-in-2-years">reported</a> earnings of $1.14 per share beating the Benzinga consensus <a href="https://www.benzinga.com/quote/TSN/earnings">estimate</a> of $0.88 by 29.5% and sales of $13.62 billion, 1.21% above the estimated $13.46 billion for the first quarter of fiscal 2025.
"Our best quarterly performance in more than two years reflects improved execution across the business, including exceptional results in chicken," said president and CEO Donnie King.
The management during its earnings call highlighted that its diversified multi-protein portfolio delivered results, with chicken helping to offset the ongoing challenges in beef. Achieving the best adjusted operating income of any quarter over the past eight years in the chicken segment.
The company&#8217;s value-added products like Jimmy Dean griddle cakes and chicken biscuits gained traction as chicken also continued to be a &#8220;bright spot,&#8221; with sales increasing due to higher volumes in these foodservice channels, explained the company CFO Curt Calaway.
Calaway raised adjusted operating income guidance for the segment to $1 billion to $1.3 billion for fiscal 2025, given the chicken&#8217;s strong first-quarter performance.
Highlighting the concerns regarding the trade war with Mexico, King added &#8220;Mexico is a large trading partner for us. So, essentially, what we would do, whether it be pork or whether it would be chicken, is we would find other markets.&#8221;
See Also: <a href="https://www.benzinga.com/news/earnings/25/02/43432806/tyson-foods-posts-q1-earnings-protein-conscious-customers-drive-demand-ceo-calls-it-best-quarter-in-2-years">Tyson Foods Posts Q1 Earnings: Protein Conscious Customers Drive Demand, CEO Calls It Best Quarter In 2 Years</a>
Why It Matters: Despite strong growth in the Chicken segment in the first quarter, the Centers for Disease Control and Prevention (CDC) on its website highlighted that H5 bird flu is widespread in wild birds globally, causing outbreaks in poultry and U.S. dairy cows, with recent human cases in U.S. farm workers. The public health risk remains low, but the CDC is closely monitoring the situation and people exposed to animals, using its flu surveillance systems.
CDC&#8217;s weekly scientific reports are on hold due to an "immediate pause" on communications by federal health agencies, ordered by Dorothy Fink, acting secretary of the Department of Health and Human Services. CNN <a href="https://edition.cnn.com/2025/01/30/health/bird-flu-mmwr-pause-trump-kff-partner/index.html">reported</a> that Fink&#8217;s memo, issued on President Donald Trump's first full day in office, requires any publication to be reviewed and approved by a presidential appointee. 
Price Action: Shares of Tyson Foods rose 2.21% to end Monday at $57.74 apiece. It fell by 0.24% in after-hours. The exchange-traded fund tracking Russell 2000, iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) declined 1.17% to $223.83 on Monday.
The average price target among 17 analysts <a href="https://www.benzinga.com/quote/TSN/analyst-ratings">tracked by Benzinga</a> is $61.38 with a ‘sell' rating. The estimates range from $45 to $75 apiece. Recent ratings from Barclays, UBS, and Piper Sandler suggest a $65 target, implying a potential upside of 12.85%.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/TSN/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="384" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04005115/Tyson-ANR-1024x384.png" alt="" class="wp-image-764001" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04005115/Tyson-ANR-1024x384.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04005115/Tyson-ANR-300x112.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04005115/Tyson-ANR-768x288.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04005115/Tyson-ANR.png 1060w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43431874/billionaire-ray-dalio-raises-valuation-concerns-as-deepseeks-new-model-hits-nvidia-stock-a-great-company-that-gets-expensive-is-much-worse-than-a-bad-company-thats-really-cheap">Billionaire Ray Dalio Raises Valuation Concerns As DeepSeek&#8217;s New Model Hits Nvidia Stock: &#8216;A Great Company That Gets Expensive Is Much Worse Than A Bad Company That&#8217;s Really Cheap&#8217;</a></li>
</ul>

Equities

Market Summary

Broad U.S. Equity ETFs

ETFs

General

Winner Winner, Chicken Dinner: Tyson Foods Q1 Beat Showcases 'Improved Execution' In Poultry, Says CEO

Flex LNG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLNG#NYSE">FLNG</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.56 by 1.79 percent. This is a 18.57 percent decrease over earnings of $0.70 per share from the same period last year. The company reported quarterly sales of $90.934 million which beat the analyst consensus estimate of $90.000 million by 1.04 percent. This is a 6.48 percent decrease over sales of $97.234 million the same period last year.

FLNG

Flex LNG Q4 2024 Adj. EPS $0.57 Beats $0.56 Estimate, Sales $90.934M Beat $90.000M Estimate

EV giant Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) had 203,221 vehicle registrations in California in 2024, nearly 12% lower than the year before, according to recent industry data.
What Happened: &#8220;Things aren't looking so golden for EV automaker Tesla in the Golden State. Tesla's dominance in the electric vehicle market continues to falter as the brand reported its fifth consecutive quarterly registration decline,&#8221; the California New Car Dealers Association (CNCDA)&nbsp; said in a statement. 
Tesla&#8217;s new registrations fell 7.8% in the fourth quarter and 11.6% in 2024. For the year, Tesla held a 52.5% share of the zero-emission vehicle market, down from the 60.1% share in 2023.
Tesla&#8217;s Model Y SUV, however, was the best-selling battery electric vehicle in the state last year with 128,923 registrations. The Model 3 sedan was the second best-selling BEV with 53,056 registrations. 
Why It Matters: Tesla&#8217;s fall in registrations in California is not inconsistent with its <a href="https://www.benzinga.com/25/01/43214246/researcher-expects-teslas-vehicle-deliveries-to-remain-flat-in-2025-contrary-to-musks-20-30-growth-prediction">overall performance last year</a>. 
The company reported a fall in vehicle deliveries for the first time in over a decade in 2024. Tesla reported global&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/25/01/42766117/tesla-stock-tumbles-on-q4-deliveries-whats-going-on" target="_blank" rel="noreferrer noopener">deliveries of 1.79 million</a>&nbsp;vehicles, down from full-year deliveries of 1.81 million in 2023, as the company attempted to ramp production of its refreshed Model 3 vehicle in a high interest rate environment. 
Tesla CEO Elon Musk&#8216;s <a href="https://www.benzinga.com/news/24/10/41479388/elon-musk-says-tesla-spacex-manufactured-in-costly-california-just-because-he-lived-there-even-as-ri">affiliation with Republican President Donald Trump</a> also likely didn&#8217;t fare well with customers of the brand in the democratic state. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43427393/tesla-rival-byd-marks-475-growth-in-january-passenger-vehicle-sales-driven-by-popularity-of-plug-in-hybrid-evs" target="_blank" rel="noreferrer noopener">Tesla Rival BYD Marks 47.5% Growth In January Passenger Vehicle Sales Driven By Popularity Of Plug-In Hybrid EVs</a></li>
</ul>
Photo courtesy: Tesla

TSLA

Tesla's Golden State Struggles: Registrations Decline In US' Largest EV Market For 5th Straight Quarter

Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) delivered a blockbuster <a href="https://www.benzinga.com/news/earnings/25/02/43449486/palantir-q4-earnings-revenue-beat-eps-beat-us-revenue-up-52-customer-count-up-43-strong-guidance-this-is-a-new-phase-unlike-anything-that-has-come-before">fourth-quarter performance</a>, positioning itself as a critical player in the artificial intelligence revolution with a 36% year-over-year revenue increase and aggressive growth across commercial and government sectors.
What Happened: The company reported fourth-quarter revenue of $827.52 million, significantly beating analyst estimates. U.S. commercial revenue soared 64% year-over-year, while the company&#8217;s total customer count expanded 43%, reflecting robust market demand for its AI platforms.
CEO Alex Karp emphasized the company&#8217;s transformative potential, stating Palantir is &#8220;making America more lethal&#8221; through its unique AI integration strategy. The company closed $1.8 billion in total contract value, with 32 deals exceeding $10 million each.
Notably, Palantir&#8217;s U.S. commercial segment saw unprecedented growth, expanding its customer base by 73% and achieving a 54% growth rate. The company&#8217;s proprietary &#8220;ontology&#8221; technology enables enterprises to effectively implement AI solutions, differentiating it from competitors.
See Also: <a href="https://www.benzinga.com/25/02/43452687/cathie-woods-ark-invest-dumps-lockheed-martin-shares-swoops-up-stock-of-this-satellite-phone-provider">Cathie Wood&#8217;s Ark Invest Dumps Lockheed Martin Shares, Swoops Up Stock Of This Satellite Phone Provider</a>
Why It Matters: Financial analysts are bullish on Palantir&#8217;s prospects. Wedbush Securities Managing Director Dan Ives described the earnings as a &#8220;massive AIP growth&#8221; and suggested the company could become &#8220;the next Oracle&#8221; with the potential for a <a href="https://www.benzinga.com/markets/equities/25/02/43452860/palantir-soars-23-after-hours-as-cramer-says-i-wont-let-you-down-and-dan-ives-calls-it-the-next-oracle-in-ai-boom">trillion-dollar market capitalization</a>.
The company&#8217;s forward guidance indicates continued momentum, with expected 2025 full-year revenue between $3.74 billion and $3.76 billion. Palantir also anticipates positive operating and net income in each quarter of 2025.
Price Action: Palantir's stock surged 22.75% to an all-time high of $102.79 in after-hours trading on Monday, following a 1.52% gain in the regular session, closing at $83.74, according to <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43453597/mohamed-el-erian-flags-market-jitters-as-tariff-pause-triggers-currency-swings-larry-summers-warns-of-trade-fallout">Mohamed El-Erian Flags Market Jitters As Trump Tariff Pause On Canada Triggers Currency Swings — Larry Summers Warns Of Trade Fallout</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

PLTR

Palantir Is 'Making America More Lethal' As Alex Karp-Led Company Secures $1.8 Billion in AI Contracts — US Commercial Customer Base Surges 73%

Viatris Inc. (VTRS) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)

Top 4 Immunology Stocks Poised For Growth In 2025

Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out

Healthcare's resilience makes it a go-to sector during market volatility. With steady demand, innovation, and aging demographics driving growth, investors could consider investing in fundamentally sound stocks like Viatris (VTRS), Bausch + Lomb Corp. (BLCO), and ACADIA Pharmaceuticals (ACAD). With strong industry tailwinds and discounted valuations, these stocks could offer solid upside potential. Continue reading… Despite market volatility, the healthcare sector remains one of the most resilient industries, thanks to its non-cyclical nature and the rising demand for medical services. As the industry evolves, companies that innovate and adapt are well-positioned for growth, offering attractive investment opportunities.
For investors, now might be an opportune time to seek out bargain hunting for healthcare stocks with strong potential, such as Viatris Inc. (<a href="https://stocknews.com/stock/VTRS/">VTRS</a>), Bausch + Lomb Corporation (<a href="https://stocknews.com/stock/BLCO/">BLCO</a>), and ACADIA Pharmaceuticals Inc. (<a href="https://stocknews.com/stock/ACAD/">ACAD</a>).
The healthcare landscape is undergoing a significant transformation with advancements in technology, evolving patient needs, and the growing complexity of medical treatments. Moreover, the aging population is increasing the need for long-term care, medical devices, and essential healthcare services.
At the same time, rising disposable income and changing lifestyles are driving higher healthcare spending, particularly on advanced treatments and pharmaceuticals. Meanwhile, hospitals are adopting bundled payment models and digital tools to enhance efficiency and cut costs.
With the global healthcare services market projected to <a href="https://www.technavio.com/report/healthcare-services-market-industry-analysis">grow by $6.26 trillion</a> at a CAGR of 8.7% between 2023 and 2028, the sector's expansion remains robust.
With that in mind, let's examine the fundamental aspects of the above-mentioned stocks in detail:
Viatris Inc. (<a href="https://stocknews.com/stock/VTRS/">VTRS</a>)
VTRS operates as a healthcare company internationally. The company operates through four segments: Developed Markets; Greater China; JANZ; and Emerging Markets. It provides prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebitda.asp">EBITDA</a> margin, VTRS' 30.48% is 440.9% higher than the 5.64% industry average. Similarly, its 27.55% trailing-12-month levered FCF margin is considerably higher than the industry average of 2.57%. Also, its trailing-12-month ROTC of 3.08% compares favorably to the negative industry average of 19.20%.
The stock's forward non-GAAP P/E multiple of 4.18x is 80.1% lower than the industry average of 20.97x. In addition, its forward EV/Sales ratio of 1.84x is 49.6% lower than the industry average of 3.66x.
During the third quarter that ended March 31, 2024, VTRS reported total revenues of $3.75 billion, and its adjusted gross profit was $2.19 billion with a margin of 58%. The company's adjusted EBITDA amounted to $1.28 billion for the quarter. In addition, its adjusted net earnings and EPS stood at $897.60 million and $0.75, respectively.
Analysts expect VTRS' EPS for the fourth quarter (ended December 2024) to come in at $0.57, while its revenue is expected to be $3.60 billion for the same period. However, VTRS' shares have lost 2.3% over the past nine months to close the last trading session at $11.20.
VTRS' bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has an A grade for Value and a B for Growth. Among 149 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry, it is ranked #37. <a href="https://stocknews.com/stock/VTRS/">Click here</a> to access additional ratings of VTRS for Momentum, Stability, Sentiment, and Quality.
Bausch + Lomb Corporation (<a href="https://stocknews.com/stock/BLCO/">BLCO</a>)
BLCO operates as an eye health company with operations across the United States, Europe, Asia, and other international markets. It operates through three segments: Vision Care; Pharmaceuticals; and Surgical, offering a diverse portfolio of around 400 products, ranging from contact lenses and eye care solutions to ophthalmic pharmaceuticals and surgical instruments.
On January 13, 2025, BLCO announced that one of its affiliates had acquired Whitecap Biosciences, LLC, a company developing two novel therapies for glaucoma and geographic atrophy (GA). This acquisition reinforces the company's commitment to expanding its clinical-stage pipeline and advancing innovative treatments in ophthalmology.
BLCO's trailing-12-month EBIT and levered FCF margins of 4.04% and 2.93% are 65.4% and 13.8% higher than their respective industry averages of 2.44% and 2.57%. In addition, its trailing-12-month ROTC of 1.04% compares to the negative industry average of 19.20%.
In terms of forward EV/Sales, BLCO is trading at 2.20x, 39.8% lower than the industry average of 3.66x. Likewise, its forward EV/EBITDA multiple of 11.96x is 9.3% lower than the industry average of 13.19x.
For the third quarter of 2024, which ended on September 30, BLCO's total revenue increased 19% year-over-year to $1.20 billion. Its operating income grew 7.5% from the year-ago value to $43 million. The company's net income amounted to $4 million or $0.01 per share compared to a loss of $84 million or $0.24 per share from the prior-year quarter. Also, its adjusted EBITDA for the quarter came in at $212 million, up 13.4% year-over-year.
Street expects BLCO's revenue for the fourth quarter (ended December 2024) to increase 6.9% year-over-year to $1.25 billion, while its EPS for the same period is expected to come in at $0.23. In addition, BLCO has topped the revenue and EPS estimates in each of the trailing four quarters, which is promising.
Over the past nine months, the stock has gained 20.2%, closing the last trading session at $17.41.
It's no surprise that BLCO has an overall rating of B, equating to a Buy in our POWR Ratings system. It also has an A grade for Value and a B for Growth. Out of 132 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry, it is ranked #34.
Beyond what is stated above, we've also rated BLCO for Momentum, Stability, Sentiment, and Quality. Get all BLCO ratings <a href="https://stocknews.com/stock/BLCO/">here</a>.
ACADIA Pharmaceuticals Inc. (<a href="https://stocknews.com/stock/ACAD/">ACAD</a>)
ACAD is a pharma company that focuses on CNS disorder treatments. Its key product is NUPLAZID for Parkinson's disease psychosis. The company is also developing DAYBUE for Rett Syndrome and has several drugs in various trial phases for conditions like schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis, Rett syndrome, and Fragile X syndrome.
On December 11, 2024, ACAD finalized the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses. As previously disclosed on November 5, 2024, Acadia will allocate one-third of the net proceeds to Neuren Pharmaceuticals Limited under their existing license agreement.
The company intends to use the remaining funds to support its commercial operations, advance R&amp;D initiatives in the central nervous system and rare diseases, and explore future business development opportunities.
 ACAD's trailing-12-month EBITDA margin of 13.40% is 137.8% higher than the industry average of 5.64%. Likewise, its trailing-12-month levered FCF margin of 23.86% compares to the industry average of 2.57%.
In terms of forward EV/Sales, ACAD is trading at 2.61x, 28.6% lower than the industry average of 3.66x. Similarly, its forward Price/Sales multiple of 3.14x is 15.5% lower than the industry average of 3.72x.
During the fiscal third quarter that ended September 30, 2024, ACAD's total revenues increased 18.3% year-over-year to $250.40 million. Its income from operations amounted to $31.64 million, versus a loss of $57.78 million in the prior year's quarter. Moreover, the company's net income and EPS stood at $32.77 million and $0.20, compared to a net loss of $65.18 million and $0.40 per share, respectively.
Analysts expect ACAD's revenue for the fourth quarter (ended December 2024) to increase 20.8% year-over-year to $279.21 million. The company's revenue for the fiscal year 2025 is expected to grow 8.4% year-over-year to $1.06 billion. Moreover, the company topped the consensus revenue estimates in three of the trailing four quarters.
Shares of ACAD have gained 23.3% over the past three months to close the last trading session at $18.40.
ACAD's robust fundamentals are apparent in its POWR Ratings. The stock has an overall rating of B, which equates to Buy in our proprietary rating system.
ACAD has an A grade for Value and Quality. Within the Medical – Pharmaceutical industry, it is ranked #35 out of 149 stocks. <a href="https://stocknews.com/stock/ACAD/">Click here</a> to access additional ACAD ratings for Growth, Momentum, Stability, and Sentiment.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
VTRS shares were trading at $11.32 per share on Wednesday afternoon, up $0.12 (+1.07%). Year-to-date, VTRS has declined -9.08%, versus a 2.91% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/vtrs-blco-acad-3-hidden-bargains-in-the-healthcare-sector/>3 Hidden Bargains in the Healthcare Sector</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Hidden Bargains in the Healthcare Sector

Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)

Viatris Inc. is a wholly owned subsidiary of Pfizer that specializes in off-patent drugs. Share price fell about 4% in the past year from $11.88 to $11.41, as of Thursday's market close.

Current Report: Viatris Inc

ABBV

ACAD

ALVO

ALVOW

AMGN

ARGX

AZNCF

BCLYF

BIIB

BLCO

BMYMP

CGEM

CHRS

FBCG

GLAXF

GMAB

GNMSF

IFRX

INCY

ITCI

LEGN

REGN

RHHBF

RHHBY

RHHVF

ROIV

SDZNY

SDZXF

SNYNF

SUPN

TEVA

TEVJF

TKPHF

TSVT

VTRS

Screenshot 2024-09-30 at 5.38.54 PM

Biotech

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Press Releases

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference

Viatris Named to Forbes' World's Top Companies for Women 2024 List

Dividends

Viatris Announces Third Quarter 2024 Dividend

Viatris Reports Third Quarter Financial Results for 2024

Mapi Pharma is Seeking New Depot Product Partnerships

Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology

Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Viatris to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

LXRX

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Viatris

Viatris (VTRS) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル